regorafenib (Stivarga®) is accepted for use within NHS Scotland – 2015

regorafenib has been approved in Scotland for treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who have progressed on or are intolerant to prior treatment with imatinib and sunitinib. This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of regorafenib and is contingent […]

Continue reading

GIST Support UK’s #100000voices Campaign 2015

March 2015 Jayne Bressington, vice chair of GIST Support UK (http://www.gistsupportuk.com/), talks to BBC Radio Humberside about the government’s plans to stop funding for the rare cancer drug Regorafenib. The petition to stop these cuts has gained 100,000+ signatures and we are now calling on everyone to write to their local parliamentary candidates ahead of […]

Continue reading

GSUK helps to fund GIST research – 2012

On 20th August we were delighted to present our medical consultant, Professor Ian Judson, with a cheque for £20,000 to help support a new research project. Professor Judson plans to collect data on all the patients who are being or have been treated at the Royal Marsden Hospital, in order to study the correlation between […]

Continue reading

SMC approves adjuvant use of Imatinib – 2012

Imatinib (Glivec) has been accepted for restricted use within Scotland for certain high risk GIST adult patients. The SMC accepted that adjuvant imatinib for three years compared to one year significantly improved survival. However, this treatment has yet to be approved by NICE for England & Wales. Click here for full details from SMC.

Continue reading

The PleurX system – 2012

This new approach to the treatment of ascites has just been approved by NICE. It comprises a catheter and collection vessel which the patient can continue to wear at home, so that he does not need to make repeated visits to hospital everytime fluid needs to be drained. Click here here to read the full text of […]

Continue reading

European Commission approves extending adjuvant therapy with Glivec to three years for certain GIST patients – 2012

Novartis announced on 27th February that the European Commission (EC) has approved an update to the Glivec® (imatinib)* label to include 36 months of treatment after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the inclusion criteria of the pivotal study. This extended treatment regimen has been shown to improve recurrence-free […]

Continue reading

MASITINIB Trial – February 2012

On 1ST February AB Science published a press release announcing encouraging results from a phase2 trial of their drug masitinib. The trial compared masitinib vs sunitinib for the second-line treatment of patients with locally advanced or metastatic imatinib-resistant GIST. Members of SPAEN and clinical experts felt at the time that AB Science’s claims were premature. […]

Continue reading